Action: A 30000 patient-years double-blind, placebo-controlled trial of nifedipine gits in stable angina

British Journal of Clinical Practice

Volumn , Issue SUPPL. 88, 1997, Pages 23-26

  Lubsen, J ^a   Poole Wilson, P A ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; NIFEDIPINE; ANTILIPEMIC AGENT; CALCIUM ANTAGONIST;

ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; HUMAN; MULTICENTER STUDY; OSMOSIS; RANDOMIZED CONTROLLED TRIAL; ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; AUSTRALIA; CANADA; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; EUROPE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HYPERCHOLESTEROLEMIA; ISRAEL; MAJOR CLINICAL STUDY; MORTALITY; NEW ZEALAND; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVASCULARIZATION; STROKE; SURVIVAL; SUSTAINED RELEASE PREPARATION;

ANGINA PECTORIS; CALCIUM CHANNEL BLOCKERS; DOUBLE-BLIND METHOD; HUMANS; NIFEDIPINE; OSMOSIS;

EID: 0031108077     PISSN: 00070947     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Psaly BM. Heckbert SR. Koepsell TD et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995: 274: 620-625.
2. Furherg CD. Psaty BM, Meyer JV. Nifedipine. Dose related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326-1331.
3. Furberg CD. Fsaty BM. Corrections to the nifedipine meta-analysis I Letter]. Circulation 1996; 93: 1475-1476.
4. Buring JE, Glynn RJ. Hennekens CH. Calcium channel blockers and myocardial infarction. A hypothesis formulated but not yet tested. I Editorial]. JAMA 1995; 274: 654-655.
5. Lenfant C. The calcium channel blocker scare. Lessons for the future. Cin-ulation 1995; 91: 2855-2856.
6. Opie LH and Messerli FH. Nifedipine and mortality. Grave detects in the dossier. Editorial. Circulation 1995; 92: 1069-1073.
7. Kloner RA. Nifedipine in isché mie heart disease [Editorial]. Circulation 1995; 92: 1074-1078.
8. Yusul S. Calcium antagonists in coronary artery disease and hypertension. Time for ré é valuation? [Editorial]. Circulation 1995; 92: 1079-1082
9. Manda G Van Zwieten PA. How safe are calcium antagonists in hypertension and coronary heart disease? J Hypertens 1996; 14: 13-17.
10. Frö hlich ED. Zanchetti A. Antihypertensive therapy: safety and efficacy of drugs and publications [Editorial!. Hypertens 1996; 27: 317-318.
11. Marwick C. PDA gives calcium channel blockers clean bill of health but warns of short-acting nifedipine hazards. JAMA 1996; 275: 423.
12. Rydé n L, Malmberg K. Calcium channel blockers or beta receptor antagonists for patients with ischaemic heart disease. What is the best choice? Editorial. Eur Heart J 1996; 17: 12.
13. Brogden RN, McTavish D. Nifedipine gastrointestinal therapeutic-system (GITS). A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and angina pecloris. Drugs 1995; 50: 495 512.
14. ACTION Study Protocol, version 6.03 dated August 27. 1996 ( 114 pages). Bayer AG, Leverkusen, Germany and SOCAR Research SA, Givrins, Switzerland.
15. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
16. Pyö rä lä K, De Backer G, Graham G et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1.300 1331.
17. Smith SC, Blair SN, Criqui MH et al (the Secondary Prevention Panel). Preventing heart attack and death in patients with coronary disease. Circulation 1995, 92: 2-4.
18. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-1122.
19. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. iMncet 1995; 345: 669-685.